Table 2.
Relationship between CXCR4 expression status and clinicopathological features in DLBCL.
| CXCR4 negative | CXCR4 positive | P value | ||
|---|---|---|---|---|
| Age | <60 ≥60 |
16 15 |
5 8 |
0.426 |
|
| ||||
| Gender | Male Female |
17 14 |
9 4 |
0.376 |
|
| ||||
| Ann Arbor stage | I-II III-IV |
17 14 |
5 8 |
0.322 |
|
| ||||
| COO | GCB Non-GCB |
25 6 |
6 7 |
0.022 |
|
| ||||
| IPI score | 0-1 ≥2 |
9 22 |
3 10 |
0.686 |
|
| ||||
| MTOR | <20% ≥20% |
21 10 |
4 9 |
0.024 |
|
| ||||
| CD5 | <50% ≥50% |
20 11 |
9 4 |
0.763 |
|
| ||||
| CD8 + T cell infiltration | <20% ≥20% |
14 17 |
8 5 |
0.322 |
|
| ||||
| C-MYC | <50% ≥50% |
15 16 |
8 5 |
0.426 |
|
| ||||
| TP53 | <50% ≥50% |
21 10 |
6 7 |
0.180 |
|
| ||||
| PD-1 | ≤1% >1% |
4 27 |
3 10 |
0.404 |
|
| ||||
| PD-L1 | ≤1% >1% |
22 9 |
10 3 |
0.686 |
Abbreviations: COO: cell of origin.